Literature DB >> 11290550

Heterogeneous vascular dependence of tumor cell populations.

J L Yu1, J W Rak, P Carmeliet, A Nagy, R S Kerbel, B L Coomber.   

Abstract

Cells within a tumor are highly heterogeneous with respect to a wide range of genotypic and phenotypic characteristics. The latter include such properties as growth, survival, invasion, and metastasis. We asked whether the degree to which individual tumor cells rely on a tumor's vasculature might also be heterogeneous. By adapting an intravital Hoechst 33342 staining technique, we labeled and isolated tumor cells based on their relative proximity to perfused vessels. Because tumor regions distal to the vasculature are likely hypoxic, we examined cells deficient for hypoxia-inducible factor-1alpha (HIF-1alpha), a transcription factor that has been shown to mediate hypoxia-induced responses, including apoptosis. Despite reduced vascularization in HIF-1alpha-/- embryonic stem cell-derived tumors, their growth in vivo was found to be accelerated relative to HIF-1alpha+/+ tumor counterparts. We hypothesized that this paradoxical observation is because of decreased apoptotic rate, resulting in diminished vascular dependence of HIF-1alpha-/- cells. Analysis of heterogeneous tumors established from mixtures of HIF-1alpha+/+ with HIF-1alpha-/- cells revealed that the proportion of cells expressing wild-type HIF-1alpha was increased in perivascular areas and decreased in distal tumor regions. Thus, cells expressing HIF-1alpha were found to be highly dependent on proximity to blood vessels for their growth and survival in vivo, whereas cells that had lost HIF-1alpha expression were much less so. Heterogeneity in angiogenesis dependence was also observed among cell subpopulations isolated from human melanoma xenografts. This potential for selection of less vascular-dependent tumor cell variants throughout the course of disease progression may have important implications for the long-term efficacy of anti-angiogenic therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11290550      PMCID: PMC1891903          DOI: 10.1016/S0002-9440(10)64083-7

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  36 in total

1.  Control of apoptosis during angiogenesis by survivin expression in endothelial cells.

Authors:  D S O'Connor; J S Schechner; C Adida; M Mesri; A L Rothermel; F Li; A K Nath; J S Pober; D C Altieri
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

2.  Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha.

Authors:  R Ravi; B Mookerjee; Z M Bhujwalla; C H Sutter; D Artemov; Q Zeng; L E Dillehay; A Madan; G L Semenza; A Bedi
Journal:  Genes Dev       Date:  2000-01-01       Impact factor: 11.361

3.  Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.

Authors:  G Klement; S Baruchel; J Rak; S Man; K Clark; D J Hicklin; P Bohlen; R S Kerbel
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

4.  Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells.

Authors:  J Tran; J Rak; C Sheehan; S D Saibil; E LaCasse; R G Korneluk; R S Kerbel
Journal:  Biochem Biophys Res Commun       Date:  1999-11-02       Impact factor: 3.575

5.  Tumor heterogeneity: biological implications and therapeutic consequences.

Authors:  G H Heppner; B E Miller
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

6.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

Authors:  T Browder; C E Butterfield; B M Kräling; B Shi; B Marshall; M S O'Reilly; J Folkman
Journal:  Cancer Res       Date:  2000-04-01       Impact factor: 12.701

Review 7.  On the genesis and regulation of cellular heterogeneity in malignant tumors.

Authors:  G Poste; R Greig
Journal:  Invasion Metastasis       Date:  1982

8.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases.

Authors:  H Zhong; A M De Marzo; E Laughner; M Lim; D A Hilton; D Zagzag; P Buechler; W B Isaacs; G L Semenza; J W Simons
Journal:  Cancer Res       Date:  1999-11-15       Impact factor: 12.701

9.  Cell selection from a murine tumour using the fluorescent probe Hoechst 33342.

Authors:  D J Chaplin; R E Durand; P L Olive
Journal:  Br J Cancer       Date:  1985-04       Impact factor: 7.640

10.  The histological structure of some human lung cancers and the possible implications for radiotherapy.

Authors:  R H THOMLINSON; L H GRAY
Journal:  Br J Cancer       Date:  1955-12       Impact factor: 7.640

View more
  35 in total

1.  Use of adenoviral vectors to target chemotherapy to tumor vascular endothelial cells suppresses growth of breast cancer and melanoma.

Authors:  Pingchuan Li; Yanzheng Liu; Jonathan Maynard; Yucheng Tang; Albert Deisseroth
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

2.  MGMT promoter methylation status in Merkel cell carcinoma: in vitro versus invivo.

Authors:  Giuseppina Improta; Cathrin Ritter; Angela Pettinato; Valeria Vasta; David Schrama; Filippo Fraggetta; Jürgen C Becker
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-12       Impact factor: 4.553

3.  Hypoxia promotes tumor cell motility via RhoA and ROCK1 signaling pathways.

Authors:  Hon S Leong; Ann F Chambers
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-07       Impact factor: 11.205

4.  Angiogenesis and melanoma - from basic science to clinical trials.

Authors:  Maxine Sylvia Emmett; Daemon Dewing; Rowan Oliver Pritchard-Jones
Journal:  Am J Cancer Res       Date:  2011-08-08       Impact factor: 6.166

5.  A new model for lymphatic metastasis: development of a variant of the MDA-MB-468 human breast cancer cell line that aggressively metastasizes to lymph nodes.

Authors:  Sharon A Vantyghem; Alison L Allan; Carl O Postenka; Waleed Al-Katib; Michael Keeney; Alan B Tuck; Ann F Chambers
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

Review 6.  Tumor heterogeneity and nanoparticle-mediated tumor targeting: the importance of delivery system personalization.

Authors:  K Laxmi Swetha; Aniruddha Roy
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

7.  Molecular and clinical aspects of targeting the VEGF pathway in tumors.

Authors:  Grzegorz Korpanty; Laura A Sullivan; Elizabeth Smyth; Desmond N Carney; Rolf A Brekken
Journal:  J Oncol       Date:  2010-06-10       Impact factor: 4.375

8.  Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors.

Authors:  Alicia Viloria-Petit; Lucile Miquerol; Joanne L Yu; Marina Gertsenstein; Capucine Sheehan; Linda May; Jack Henkin; Corrinne Lobe; Andras Nagy; Robert S Kerbel; Janusz Rak
Journal:  EMBO J       Date:  2003-08-15       Impact factor: 11.598

Review 9.  Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?

Authors:  Alessia Bottos; Alberto Bardelli
Journal:  Cell Mol Life Sci       Date:  2013-05-18       Impact factor: 9.261

10.  Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2.

Authors:  Rebekah R White; Siqing Shan; Christopher P Rusconi; Geetha Shetty; Mark W Dewhirst; Christopher D Kontos; Bruce A Sullenger
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.